Lannett Company Inc (NYSE: LCI), a company that develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications, announced yesterday that it has named John Kozlowski as its new chief financial officer effective 31 August 2019.
Kozlowski succeeds Martin Galvan, who will retire on 30 August 2019, following the planned submission of the company's Form 10-K for fiscal year 2019. He presently serves as the company's chief of staff and strategy officer.
Prior to joining Lannett, Kozlowski held senior finance positions with Finisar Australia (formerly Optium Australia) and Optium Corporation. He has a Master of Business Administration degree from Rider University and a Bachelor's degree in finance from James Madison University.
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
International Isotopes Inc to change name to Radnostix Inc
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
EirGenix signs second global exclusive licensing deal with Sandoz
Padagis invests USD36m to expand manufacturing in Minneapolis
Newbury Pharmaceuticals gains Danish approval for generic ivermectin cream